Canagliflozin Prostate Cancer Breakthrough | McMaster Research
McMaster University researchers reveal canagliflozin's role as a novel androgen receptor inhibitor for castrate-sensitive and resistant prostate cancer, offering new hope amid Canada's 29,300 projected cases in 2026.

